Crohn’s disease, particularly in patients experiencing bowel urgency, is associated with a significant impact on quality of life, yet effective targeted therapies for bowel urgency remain limited despite emerging biologic options. To address this gap, a study evaluated the efficacy of mirikizumab, an interleukin-23p19 inhibitor, in achieving early bowel urgency response and remission, along with exploring associations between disease characteristics, baseline bowel urgency, and its resolution in 778 patients with Crohn’s disease.
The study found that 94.2% of participants had a baseline Urgency Numeric Rating Scale (NRS) score ≥3, with bowel urgency showing a positive correlation with Crohn’s Disease Activity Index and abdominal pain scores. Mirikizumab treatment resulted in significantly greater improvement in bowel urgency from baseline as early as week 6, with sustained benefits…
